Clinical trials: CRC Screening
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Colorectal Cancer
Adherence to Minimally Invasive Testing
Colorectal cancer (CRC) screening has been demonstrated to reduce long term disease burden and costs. Unfortunately, less than 65 % of age-eligible persons in the US are actually screened for CRC.
- Trial name
- ADMIT (NCT02251782)
- Testing
- Epi proColon Test, Fecal Immunochemical Test (FIT)
- Where
- 2 sites in United States
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Metastatic Colorectal Cancer (mCRC)
Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer
DSEE-CRC is a top-tier Norwegian and Swedish public-private partnership for the development of µCAN, a unique patient-centric, therapy-guiding in vitro diagnostic test to improve cancer treatment outcomes for metastatic…
- Trial name
- DSEE-CRC (NCT07171554)
- Testing
- µCAN drug screen test, Standard-of-Care Therapy
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oncosyne AS
Colo-rectal Cancer
Motility of the Check-cap's MD1 Colon Capsule in Subjects Following Colon Rectal Cancer Screening by Colonoscopy
To monitor the Whole Gut Transit Time and repeatability of the motility of MD1 capsules in the colon of subjects with known polyps and in healthy subjects. Multi-Center, Open, Home Monitoring, Prospective Study.
- Trial name
- NCT03785665
- Testing
- MDI
- Where
- Israel
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Check-Cap Ltd.
Colorectal Cancer Screening, Colorectal Cancer
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
This is a prospective longitudinal study to assess the impact of repeat Cologuard testing at 3 years in average risk patients.
- Trial name
- NCT02419716
- Testing
- Cologuard
- Where
- 40 sites in United States
- Volunteers
- 2,404 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
CRC
Evaluation of the Motus GI CleanUp System During Screening Colonoscopy
Motus GI is developing a single-use device that attaches to a standard colonoscope, thereby integrating colon cleansing, screening and treatment into one procedure. The device creates turbulence within the colon using water jets.
- Trial name
- NCT01838980
- Testing
- Motus GI Clean-Up Device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Motus GI Medical Technologies Ltd
Colorectal Cancer
Head to Head Study Epi proColon and FIT
The study aims to show non-inferiority in the clinical performance of the investigational assay, Epi proColon, to FIT using matched blood and stool specimens from screening-guideline eligible subjects.
- Trial name
- NCT01580540
- Where
- 70 sites in United States, Puerto Rico
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Colorectal Neoplasms, Digestive System Diseases
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method.
- Conditions
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
- Trial name
- DeeP-C (NCT01397747)
- Where
- 184 sites in United States, Canada
- Volunteers
- 12,776 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
CRC Screening
Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon
This study was design to establish the effectiveness of PillCam® Platform with the PillCam® COLON 2 capsule as demonstrated by the identification of subjects with polyps as compared to optical colonoscopy.
- Trial name
- NCT01372878
- Testing
- PillCam® COLON 2 procedure, Colonoscopy
- Where
- 17 sites in United States, Israel
- Volunteers
- 884 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Colorectal Cancer
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
- Trial name
- NCT03728348
- Testing
- mt-sDNA screening test, Colonoscopy
- Where
- 39 sites in United States
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Colorectal Cancer, Colorectal Polyp
Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical…
- Conditions
- Colorectal Cancer, Colorectal Polyp, Colorectal Adenoma, Colorectal Adenomatous Polyp
- Trial name
- NCT05988645
- Testing
- MiWEndo System
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- MiWEndo Solutions S.L.
Colorectal Cancer (Diagnosis)
Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study
The primary objective of this study is to evaluate a blood-based screening test for Colorectal Cancer (CRC).
- Trial name
- CLEAR (NCT07479381)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Harbinger Health
Colorectal Cancer Screening, Advanced Adenomas (AA)
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
The goal of this Multicentre and international prospective study is to validate a molecular signature using plasma samples in average-risk population for colorectal cancer who undergo colonoscopy in a screening setting.
- Trial name
- NCT06738511
- Testing
- blood sampling, stool sampling, colonoscopy
- Where
- 2 sites in Germany, Poland
- Volunteers
- 3,421 people, healthy volunteers welcome
- Sponsor
- ADVANCED MARKER DISCOVERY S.L.
Colorectal Cancer, Adenoma Colon
Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy
This is a prospective, multicenter, randomized study to evaluate the clinical performance of a novel CADe device, WISE VISION® Endoscopy System, in patients undergoing high-definition white light (HDWL) colonoscopy for screening…
- Conditions
- Colorectal Cancer, Adenoma Colon, Polyp of Colon
- Trial name
- COLOWISE (NCT05611151)
- Testing
- Computer Aided Detection (CADe)
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 830 people
- Sponsor
- NEC Corporation
Colorectal Cancer
Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States and affects men and women almost equally.
- Trial name
- NCT01574677
- Where
- 2 sites in United States
- Sponsor
- Epigenomics, Inc
Colonoscopy (Procedure)
Use of GI Genius™ XR Software in Virtual Reality Headset During Routine Colonoscopy
This pilot study will evaluate the usability and safety of software GI Genius™ XR in the Apple Vision Pro™ virtual reality headset when used in conjunction with the GI Genius™ system during routine screening and surveillance…
- Trial name
- NCT07220174
- Testing
- software GI Genius™ XR on headset
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cosmo Artificial Intelligence-AI Ltd
Pain, Cancer
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy.
- Conditions
- Pain, Cancer, Colonic Diseases
- Trial name
- NCT01926444
- Testing
- GIC-1001
- Where
- 15 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- gicare Pharma Inc.
Colo-rectal Cancer
Shield Post-Approval Study Protocol
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing…
- Trial name
- SOLAR (NCT06880055)
- Testing
- Shield Blood Test for colo-rectal cancer Screening
- Where
- 69 sites in United States
- Volunteers
- 3,375 people, healthy volunteers welcome
- Sponsor
- Guardant Health, Inc.
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of Personalized Neoantigen Cancer Vaccines
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03794128
- Testing
- Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
- Where
- 5 sites in United States
- Volunteers
- 93 people
- Sponsor
- Gritstone bio, Inc.
Colorectal Cancer Screening
Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening
mPATH-CRC (mobile Patient Technology for Health) is an automated direct-to-patient digital health program about colorectal cancer screening.
- Trial name
- NCT06821009
- Testing
- mPATH-CRC, Usual Care (Control)
- Where
- 2 sites in United States
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Digital Health Navigation Solutions, Inc